Medical Oncologist
Hyderabad's Dedicated Small Intestinal Cancer Panel
Best Intestinal Cancer Doctors in Hyderabad — CION's Dedicated Small Intestinal Cancer Panel
"Intestinal cancer" in medical usage typically means cancer of the small intestine (duodenum, jejunum, ileum) — rare (~3% of GI cancers), but its four subtypes (adenocarcinoma, NET, GIST, lymphoma) are treated completely differently. Getting the subtype right is the single most consequential decision. CION operates Hyderabad's dedicated small intestinal cancer panel across 11 locations, with DrNB-trained GI surgical oncologist Dr. Sridhar Kamani leading our small bowel pathway.
- DrNB-trained GI surgical lead — Dr. Sridhar Kamani (DrNB Surgical Gastroenterology) leads small bowel surgery
- Subtype confirmed before treatment — adenocarcinoma vs GIST vs NET vs lymphoma decides everything
- Subtype-specific systemic therapy — FOLFOX/CAPOX · imatinib · somatostatin analogues · PRRT · R-CHOP
- Free written second opinion — tumour-board reviewed, documented, yours to keep
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The CION Small Intestinal Cancer Panel
16 specialists, one team. Adenocarcinoma, NET & GIST pathways.
Surgical, medical, and radiation oncology spanning adenocarcinoma, neuroendocrine tumours, GIST, and small bowel lymphoma — with haematology consultation added for lymphoma cases. Use the tabs to filter by specialty; request a specific doctor by name when booking.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Specialist Disambiguation
Which Type of Doctor Actually Treats Small Intestinal Cancer?
Small intestinal cancer is the cancer where the wrong subtype identification most consistently leads to wrong treatment. A patient with GIST given conventional FOLFOX chemotherapy will not respond and will lose months. A patient with NET given the same treatment will see no real benefit when somatostatin analogues and PRRT could meaningfully extend life. The good news is that the pathology and molecular tests required to make these distinctions are well-established — they just have to be done.
| Specialist | What they treat | When you need them for small intestinal cancer |
|---|---|---|
| Gastroenterologist | Digestive system diseases — including specialised small bowel endoscopy (capsule endoscopy, balloon enteroscopy) | Critical diagnostic role — performs the specialised endoscopy needed to find and biopsy small bowel cancers. Does not lead treatment. Refers to surgical oncology once cancer is confirmed. |
| General Surgeon | General abdominal surgery, including small bowel resection | Can technically perform small bowel resection but typically lacks the onco-specific training and broader oncology team coordination required. For confirmed cancer, an onco-trained surgeon is preferred. |
| Surgical Gastroenterologist | GI surgery sub-specialty — including small bowel resection, pancreatic surgery, and biliary surgery | Strong technical fit for small intestinal cancer surgery, particularly tricky duodenal cases. Best paired with an oncology team for adjuvant therapy coordination. |
| Surgical Oncologist (GI-trained) | All cancer surgeries with GI sub-specialty training | The right surgeon for small intestinal cancer. Trained in segmental small bowel resection with lymph node dissection, right hemicolectomy for ileal NETs, and Whipple-type procedures for duodenal cancer. |
| Medical Oncologist | Systemic cancer treatment — subtype-specific protocols | Essential — each small intestinal cancer subtype needs different systemic therapy. Adenocarcinoma: FOLFOX/CAPOX. GIST: imatinib (a TKI). NET: somatostatin analogues, everolimus, PRRT. Lymphoma: R-CHOP. A generic chemotherapy approach is the most common avoidable error. |
| Radiation Oncologist | Radiation therapy | Selective role — adjuvant radiation for select duodenal cancers, palliative radiation for symptomatic disease, and as part of lymphoma protocols where indicated. |
Which specialist should you see first?
Use this as a quick guide. Your specific situation may vary; any CION oncologist can review your case in 45 minutes and tell you which subspecialty should lead your care.
- Unexplained abdominal pain, anaemia, or weight loss; standard endoscopy and colonoscopy normalAsk about capsule endoscopy or balloon enteroscopy. The small bowel needs different tools.
- Biopsy confirms small intestinal cancerInsist on pathology subtype confirmation (adenocarcinoma vs GIST vs NET vs lymphoma) before any treatment plan. Surgical oncology and medical oncology must lead together.
- Diagnosis is small bowel adenocarcinomaSurgery (segmental resection or Whipple for duodenal cases) followed by FOLFOX or CAPOX adjuvant chemotherapy.
- Diagnosis is small bowel GISTSurgery, then imatinib (a tyrosine kinase inhibitor) — NOT conventional chemotherapy. Molecular testing (KIT, PDGFRA) guides treatment.
- Diagnosis is small bowel NET / carcinoidSurgery where feasible, somatostatin analogues, possibly everolimus or sunitinib, and PRRT (Lu-177 dotatate) for advanced cases. Ki-67 grading matters.
- Diagnosis is small bowel lymphomaMedical oncology / haematology leads with R-CHOP or subtype-specific lymphoma chemotherapy. Surgery only in select cases.
The honest answer is that small intestinal cancer requires a coordinated team that can pivot treatment based on the exact subtype — not a single surgeon working alone. The decision that matters most is choosing the team.
Patient Decision Framework
Seven Questions to Ask Before You Choose a Small Intestinal Cancer Doctor
Most small intestinal cancer patients arrive at oncology already exhausted by months of diagnostic uncertainty. The instinct now is to start treatment immediately. But for this cancer, the diagnosis is only half the question — the subtype determines everything that follows, and the wrong treatment for the wrong subtype can lose months. Bring these seven questions to your first consultation — at CION, or anywhere else.
How many small intestinal cancer cases does this team treat in a year — and how many will be personally led by my doctor?
Small intestinal cancer is rare. Most centres see only a handful of cases per year. Volume creates the pattern recognition this cancer demands — particularly around subtype-specific treatment selection.
What type of small intestinal cancer do I have — and how does the treatment change for each type?
Adenocarcinoma, GIST, NET, and lymphoma are all called "small intestinal cancer" but are treated completely differently. A team willing to walk you through the four subtypes — and what tests confirm yours — is a team that takes this seriously.
How much of my intestine will be removed — and will I be able to eat and digest normally afterwards?
Surgery varies by tumour location. Duodenal cancers may need Whipple. Jejunal and ileal cancers need segmental resection. Most patients can eat normally after recovery, but the conversation should happen pre-op, not after.
Who will personally manage my case across surgery, systemic therapy, and follow-up?
Small intestinal cancer often runs over years of follow-up — particularly for NETs, where surveillance scans, somatostatin analogue management, and PRRT decisions need continuity. The doctor who sees you across visits is the one most likely to catch what matters.
Will I get a written cost estimate covering everything — before treatment starts?
Costs vary dramatically by subtype — imatinib for GIST runs for years, PRRT for NETs is expensive per cycle, FOLFOX/CAPOX runs for 6 months. Diagnostics, pathology, follow-up imaging, and medicines can add 30–50% you were not told about.
How much time will I actually have to ask questions and understand my options?
A seven-minute consultation cannot honestly unpack a small intestinal cancer diagnosis — particularly the subtype distinction that determines everything else. Especially not in a second language.
Will my case be discussed by a team of specialists together, or decided by one person?
Small intestinal cancer decisions cut across surgical, medical, and radiation oncology, with haematology added for lymphoma cases. No single doctor sees the full picture alone.
We mean it: take this list to any consultation — ours or anyone else's. Mention the questions when you sit down with the doctor. A centre worth choosing will welcome them.
Our Standards, in Numbers
How CION Measures Up
Every standard below maps to a concern patients carry into their first consultation. We did not build these to look good on a webpage. We built them because they are what we would want if it were our family with the diagnosis.
DrNB-trained GI surgical lead
Dr. Sridhar Kamani (DrNB Surgical Gastroenterology, FMAS, FIAGES) leads our small bowel cancer pathway — including the more technically demanding duodenal and ileal cases.
45-minute first consultation
Six times the corporate-hospital default. Real time to understand a rare diagnosis.
Subtype confirmed before treatment
Every small intestinal cancer case has pathology review and molecular testing to confirm adenocarcinoma, GIST, NET, or lymphoma — before any treatment begins.
Subtype-specific systemic therapy
FOLFOX/CAPOX for adenocarcinoma. Imatinib for GIST. Somatostatin analogues + targeted therapy for NET. R-CHOP for lymphoma. Generic chemotherapy is never the answer.
Multidisciplinary tumour board for every case
Surgical, medical, and radiation oncology — together — before any decision. Haematology consultation added for lymphoma cases.
PRRT coordination for advanced NETs
Peptide receptor radionuclide therapy (Lu-177 dotatate) for advanced neuroendocrine tumours coordinated with accredited nuclear medicine partners.
Specialised endoscopy access
Capsule endoscopy and balloon enteroscopy arranged through partner gastroenterology where needed for diagnosis or surveillance.
Adjuvant chemotherapy delivered to NCCN protocol
Post-resection adjuvant chemotherapy where indicated — many small bowel cancer patients are not offered adjuvant therapy at general centres even when guidelines support it.
One named lead specialist
From first consultation through surgery, systemic therapy, and follow-up. No rotating juniors.
Written, itemised cost estimate
Surgery, subtype-specific chemo or targeted therapy, follow-up imaging — quoted in writing before treatment begins.
Telugu · Hindi · English consultations
In the language you actually think in. Family members are encouraged to attend.
Free written second opinion
Documented. Yours to keep. Take it to any doctor, anywhere — including our competitors.
Every number above is independently verifiable on request — ask any CION specialist for the underlying details and they will give them to you.
Operationally, Not in Marketing Language
How a Small Intestinal Cancer Case Actually Moves Through CION
From your first call to your final follow-up, here is how your case moves through CION.
First Consultation (45 minutes)
A senior oncologist reviews your case in full. If you have a recent CT, capsule endoscopy report, or biopsy, we review what you already have. The four-subtype framework is introduced at this stage. Family welcome. Telugu, Hindi, or English.
Pathology Subtype Confirmation
This is the central step. Biopsy slides are reviewed by our oncology pathologist. Immunohistochemistry confirms whether the tumour is adenocarcinoma (CK7, CK20), GIST (KIT, DOG1), NET (chromogranin A, synaptophysin, Ki-67 grade), or lymphoma. Molecular testing follows for GIST (KIT/PDGFRA mutation analysis) and as needed for others.
Staging and Functional Assessment
CT chest, abdomen, and pelvis for staging. For NETs, Ga-68 DOTATATE PET-CT is arranged to confirm somatostatin receptor expression and detect metastases. For lymphoma, full lymph node and bone marrow assessment.
Multidisciplinary Tumour Board Discussion
Your case is presented to surgical oncology, medical oncology, and where indicated radiation oncology and haematology — together — usually within five working days. The team's recommendation on subtype-specific treatment sequence is documented.
Treatment Plan with Named Lead Doctor
You meet your lead specialist. The full plan is explained in your preferred language — including the surgical approach, the subtype-specific systemic therapy, and what follow-up looks like. You receive a written, itemised cost estimate before anything begins.
Treatment
Segmental small bowel resection, Whipple for duodenal cancers, or right hemicolectomy for ileal NETs — performed by GI surgical oncology. Subtype-specific systemic therapy delivered: FOLFOX/CAPOX, imatinib, somatostatin analogues + targeted therapy, R-CHOP, or PRRT (coordinated with accredited nuclear medicine for NETs). The same lead doctor remains accountable for your case throughout.
Follow-Up and Surveillance
Follow-up varies by subtype. Adenocarcinoma: every 3 months for 2 years, then 6-monthly. NET: long-term Ga-68 DOTATATE PET and chromogranin A monitoring. GIST: imatinib continuation and 6-monthly CT. Lymphoma: standard lymphoma surveillance. Your lead doctor stays the same.
If at any stage you want a second opinion — internal or external — we facilitate it. Free, in writing, yours to keep.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Common questions
Frequently Asked Questions
What does intestinal cancer mean — is it the same as colon cancer?
In medical usage, intestinal cancer typically refers to small intestinal cancer (also called small bowel cancer) — cancer of the duodenum, jejunum, or ileum. This is distinct from colon cancer and rectal cancer, which affect the large intestine. Small intestinal cancer is rare (around 3% of GI cancers) but its subtypes — adenocarcinoma, neuroendocrine tumour (NET), gastrointestinal stromal tumour (GIST), and lymphoma — each have completely different treatments. Getting the subtype right is essential before treatment begins.
Who is the best intestinal cancer doctor in Hyderabad?
The best doctor depends on your subtype and tumour location. For surgery, look for a surgical oncologist with GI sub-specialty training (DrNB Surgical Gastroenterology or M.Ch Surgical Oncology), especially for tricky duodenal or ileal cases. For chemotherapy and targeted therapy, look for a medical oncologist with breadth across adenocarcinoma, GIST, and NET regimens. At CION, every small intestinal cancer case is reviewed by a multidisciplinary tumour board, with surgery led by Dr. Sridhar Kamani (DrNB Surgical Gastroenterology).
What type of small intestinal cancer do I have — and how does the treatment change?
This is the most important question in small intestinal cancer. The four major subtypes are treated completely differently. Adenocarcinoma (the most aggressive type) is treated primarily with surgery followed by FOLFOX or CAPOX chemotherapy. Neuroendocrine tumours (NETs, including carcinoid) are treated with surgery, somatostatin analogues (octreotide, lanreotide), everolimus, sunitinib, and increasingly PRRT (Lu-177 dotatate) — and grow much more slowly than adenocarcinoma. Gastrointestinal stromal tumours (GIST) are treated with imatinib (a targeted therapy), NOT conventional chemotherapy. Lymphoma is treated with R-CHOP chemotherapy, sometimes after surgery. A team that does not confirm subtype with proper pathology and molecular workup before starting treatment is taking a serious risk.
How much of my intestine will be removed — and will I be able to eat normally afterwards?
The amount removed depends on location and stage. For duodenal cancers, a Whipple procedure (or pancreas-preserving variant) may be needed because the duodenum is anatomically attached to the pancreas and bile duct. For jejunal or ileal cancers, segmental resection of the affected bowel segment with reconnection (anastomosis) is typical. For ileal NETs, a right hemicolectomy is often done. The small intestine has significant reserve — most patients can eat and digest normally after recovery, though some adjustments around portion size, fat absorption, and vitamin B12 (for ileal resection) may be needed. The CION post-resection pathway includes dietitian support.
Why did my small intestinal cancer take so long to diagnose?
Small intestinal cancer is notoriously difficult to diagnose because symptoms are vague (abdominal pain, weight loss, anaemia, occasional bleeding) and the small intestine is harder to examine than the stomach or colon. Standard upper endoscopy and colonoscopy do not reach most of the small bowel. Specialised diagnostic tools — capsule endoscopy (a swallowable camera capsule) and balloon enteroscopy — are needed but not available at every centre. Diagnostic delay is common and not your fault; what matters now is making sure your treatment is led by a specialist team.
Is GIST the same as small intestinal adenocarcinoma?
No — they are completely different cancers and treated completely differently. GIST (gastrointestinal stromal tumour) arises from the interstitial cells of Cajal in the bowel wall, while adenocarcinoma arises from the cells lining the bowel. GIST is treated with surgery and imatinib (a tyrosine kinase inhibitor); standard chemotherapy has no meaningful activity against GIST. Adenocarcinoma is treated with surgery and FOLFOX/CAPOX chemotherapy. Pathology accuracy in distinguishing the two is critical — CION's tumour board ensures proper subtype identification before any treatment decision.
What is a neuroendocrine tumour (NET) of the small bowel?
Neuroendocrine tumours (also called carcinoid tumours) of the small bowel arise from the hormone-producing cells lining the intestine. They typically grow slowly, may secrete hormones causing flushing, diarrhoea, or carcinoid syndrome, and behave very differently from adenocarcinoma. Treatment includes surgery, somatostatin analogues (octreotide, lanreotide), targeted therapy (everolimus, sunitinib), and increasingly PRRT (peptide receptor radionuclide therapy with Lu-177 dotatate). NETs have meaningfully better long-term survival than adenocarcinoma. CION coordinates NET care including PRRT through accredited nuclear medicine partners.
Should I see a gastroenterologist or an oncologist for intestinal cancer?
A gastroenterologist plays an important diagnostic role — performing capsule endoscopy, balloon enteroscopy, and biopsy that confirm small intestinal cancer. But once cancer is confirmed, treatment must be led by oncology: a surgical oncologist with GI training for surgery, and a medical oncologist current with the relevant subtype's systemic therapy. A general gastroenterologist alone cannot direct small intestinal cancer treatment.
How do I get a second opinion for intestinal cancer in Hyderabad?
A second opinion is especially valuable for small intestinal cancer because subtype identification and treatment vary so dramatically. At CION the second opinion is free, written, and yours to keep — our multidisciplinary tumour board reviews your pathology slides, imaging, and existing recommendation and provides a documented opinion you can take anywhere.
How much does intestinal cancer treatment cost in Hyderabad?
Costs vary widely by subtype and stage. Small bowel resection ranges approximately ₹2,00,000 to ₹5,00,000; Whipple procedure for duodenal cancer ranges ₹4,00,000 to ₹8,00,000+; FOLFOX or CAPOX chemotherapy adds ₹1,50,000 to ₹4,00,000 over six months; imatinib for GIST runs significantly per month and continues for years; PRRT for NETs is significantly higher per cycle. For a detailed cost breakdown by treatment type, see our small intestinal cancer treatment in Hyderabad page. Every CION patient receives a written, itemised cost estimate before treatment begins. Aarogyasri, EMI, and cashless insurance are accepted.
Take the next step with a team that does this every day
DrNB-trained GI surgical lead. Subtype confirmation with full pathology and molecular workup before treatment. Subtype-specific systemic therapy — FOLFOX/CAPOX, imatinib, somatostatin analogues, R-CHOP, PRRT — matched to your exact diagnosis. Multidisciplinary tumour board for every patient. Free 45-minute consultation. NABH-accredited. Aarogyasri, EMI, and cashless insurance accepted.
This content is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified oncologist for guidance specific to your medical condition. The information on this page is periodically reviewed and updated by CION's medical team in accordance with current clinical guidelines.